Literature DB >> 18287964

IGF-2 and FLT-1/VEGF-R1 mRNA levels reveal distinctions and similarities between congenital and common infantile hemangioma.

Arnaud Picard1, Elisa Boscolo, Zia A Khan, Tatianna C Bartch, John B Mulliken, Marie Paule Vazquez, Joyce Bischoff.   

Abstract

Common infantile hemangioma appears postnatally, grows rapidly, and regresses slowly. Two types of congenital vascular tumors present fully grown at birth and behave differently from infantile hemangioma. These rare congenital tumors have been designated rapidly involuting congenital hemangioma (RICH) and noninvoluting congenital hemangioma (NICH). RICH and NICH are similar in appearance, location, and size, and have some overlapping histologic features with infantile hemangioma. At a molecular level, neither expresses glucose transporter-1, a diagnostic marker of infantile hemangioma. To gain further insight into the molecular differences and similarities between congenital and common hemangioma, we analyzed expression of insulin-like growth factor-2, known to be highly expressed in infantile hemangioma and VEGF-receptors, by quantitative real-time PCR, in three RICH and five NICH specimens. We show that insulin-like growth factor-2 mRNA was expressed in both RICH and NICH, at a level comparable with that detected in common hemangioma over 4 y of age. In contrast, mRNA levels for membrane-associated fms-like tyrosine-kinase receptor, also known as VEGF receptor-1, were uniformly increased in congenital hemangiomas compared with proliferating or involuting phase common hemangioma. These results provide the first evidence of the molecular distinctions and similarities between congenital and postnatal hemangioma.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18287964      PMCID: PMC2810617          DOI: 10.1203/PDR.0b013e318163a243

Source DB:  PubMed          Journal:  Pediatr Res        ISSN: 0031-3998            Impact factor:   3.756


  13 in total

Review 1.  Gene quantification using real-time quantitative PCR: an emerging technology hits the mainstream.

Authors:  David G Ginzinger
Journal:  Exp Hematol       Date:  2002-06       Impact factor: 3.084

2.  Neuropilin-2 is a receptor for the vascular endothelial growth factor (VEGF) forms VEGF-145 and VEGF-165 [corrected].

Authors:  Z Gluzman-Poltorak; T Cohen; Y Herzog; G Neufeld
Journal:  J Biol Chem       Date:  2000-06-16       Impact factor: 5.157

3.  Congenital hemangioma: evidence of accelerated involution.

Authors:  L M Boon; O Enjolras; J B Mulliken
Journal:  J Pediatr       Date:  1996-03       Impact factor: 4.406

4.  Insulin-like growth factor 2 and potential regulators of hemangioma growth and involution identified by large-scale expression analysis.

Authors:  Matthew R Ritter; Michael I Dorrell; Joseph Edmonds; Sheila Fallon Friedlander; Martin Friedlander
Journal:  Proc Natl Acad Sci U S A       Date:  2002-05-28       Impact factor: 11.205

5.  Noninvoluting congenital hemangioma: a rare cutaneous vascular anomaly.

Authors:  O Enjolras; J B Mulliken; L M Boon; M Wassef; H P Kozakewich; P E Burrows
Journal:  Plast Reconstr Surg       Date:  2001-06       Impact factor: 4.730

6.  GLUT1: a newly discovered immunohistochemical marker for juvenile hemangiomas.

Authors:  P E North; M Waner; A Mizeracki; M C Mihm
Journal:  Hum Pathol       Date:  2000-01       Impact factor: 3.466

7.  Regulation of glut1 mRNA by hypoxia-inducible factor-1. Interaction between H-ras and hypoxia.

Authors:  C Chen; N Pore; A Behrooz; F Ismail-Beigi; A Maity
Journal:  J Biol Chem       Date:  2000-12-18       Impact factor: 5.157

8.  Neuropilin-1 is expressed by endothelial and tumor cells as an isoform-specific receptor for vascular endothelial growth factor.

Authors:  S Soker; S Takashima; H Q Miao; G Neufeld; M Klagsbrun
Journal:  Cell       Date:  1998-03-20       Impact factor: 41.582

9.  Rapidly involuting congenital hemangioma: clinical and histopathologic features.

Authors:  Beatriz Berenguer; John B Mulliken; Odile Enjolras; Lawrence M Boon; Michel Wassef; Patrice Josset; Patricia E Burrows; Antonio R Perez-Atayde; Harry P W Kozakewich
Journal:  Pediatr Dev Pathol       Date:  2003 Nov-Dec

10.  Flt-1, a receptor for vascular endothelial growth factor, has transforming and morphogenic potentials.

Authors:  Y Maru; S Yamaguchi; M Shibuya
Journal:  Oncogene       Date:  1998-05       Impact factor: 9.867

View more
  11 in total

1.  Rapidly involuting congenital haemangioma (RICH) of the liver.

Authors:  Derek Roebuck; Neil Sebire; Eldon Lehmann; Alex Barnacle
Journal:  Pediatr Radiol       Date:  2012-03

2.  VEGFR-1 mediates endothelial differentiation and formation of blood vessels in a murine model of infantile hemangioma.

Authors:  Elisa Boscolo; John B Mulliken; Joyce Bischoff
Journal:  Am J Pathol       Date:  2011-09-21       Impact factor: 4.307

3.  Vascular tumors.

Authors:  Abel Sepulveda; Edward P Buchanan
Journal:  Semin Plast Surg       Date:  2014-05       Impact factor: 2.314

Review 4.  Vasculogenesis in infantile hemangioma.

Authors:  Elisa Boscolo; Joyce Bischoff
Journal:  Angiogenesis       Date:  2009-05-10       Impact factor: 9.596

Review 5.  Pathogenesis of infantile haemangioma.

Authors:  S Greenberger; J Bischoff
Journal:  Br J Dermatol       Date:  2013-07       Impact factor: 9.302

Review 6.  The role of mRNA in the development, diagnosis, treatment and prognosis of neural tumors.

Authors:  Yiyang Zheng; Yanyan Luo; Xixi Chen; Huiting Li; Baojun Huang; Baofeng Zhou; Liqing Zhu; Xianhui Kang; Wujun Geng
Journal:  Mol Cancer       Date:  2021-03-05       Impact factor: 27.401

Review 7.  Biology of infantile hemangioma.

Authors:  Tinte Itinteang; Aaron H J Withers; Paul F Davis; Swee T Tan
Journal:  Front Surg       Date:  2014-09-25

8.  Author's reply.

Authors:  Vaibhav Pandey; An Gangopadhyay; Preeti Tiwari; Dk Gupta; Sp Sharma; Vijayendar Kumar
Journal:  J Cutan Aesthet Surg       Date:  2014-04

Review 9.  Propranolol for the treatment of vascular sarcomas.

Authors:  Michael J Wagner; Lee D Cranmer; Elizabeth T Loggers; Seth M Pollack
Journal:  J Exp Pharmacol       Date:  2018-09-06

10.  Suppressed NFAT-dependent VEGFR1 expression and constitutive VEGFR2 signaling in infantile hemangioma.

Authors:  Masatoshi Jinnin; Damian Medici; Lucy Park; Nisha Limaye; Yanqiu Liu; Elisa Boscolo; Joyce Bischoff; Miikka Vikkula; Eileen Boye; Bjorn R Olsen
Journal:  Nat Med       Date:  2008-10-19       Impact factor: 53.440

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.